CBD getting some positive attention today! FDA
Post# of 3448
(Total Views: 153)
Posted On: 04/19/2018 2:56:05 PM
CBD getting some positive attention today!
FDA panel unanimously backs GW Pharma's cannabis-based epilepsy drug
(Reuters) - GW Pharmaceuticals Plc’s cannabis-derived drug to treat a severe form of childhood epilepsy was unanimously backed on Thursday by an advisory panel to the U.S. Food and Drug Administration.
The 13-to-0 vote sets the stage for the approval of the first-ever cannabis-derived treatment in the United States.
The panel’s backing was widely expected, after FDA staff on Tuesday gave a favorable review citing findings from three clinical studies that showed the drug reduced frequency of seizures in patients with the disease when added to a current therapy.
The FDA does not have to act on the recommendations of its experts, but typically does.
A potential approval of the drug, Epidiolex, a final decision on which is due by June 27, would confirm the therapeutic benefits of cannabidiol (CBD) - an active ingredient found in marijuana from which the drug is derived.
Epidiolex is designed to treat Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), rare childhood-onset forms of epilepsy that are among the most resistant to treatment.
“There is little evidence that CBD has meaningful abuse potential,” an FDA staffer said during the meeting.
https://www.reuters.com/article/us-gw-fda/fda...SKBN1HQ2CG
FDA panel unanimously backs GW Pharma's cannabis-based epilepsy drug
(Reuters) - GW Pharmaceuticals Plc’s cannabis-derived drug to treat a severe form of childhood epilepsy was unanimously backed on Thursday by an advisory panel to the U.S. Food and Drug Administration.
The 13-to-0 vote sets the stage for the approval of the first-ever cannabis-derived treatment in the United States.
The panel’s backing was widely expected, after FDA staff on Tuesday gave a favorable review citing findings from three clinical studies that showed the drug reduced frequency of seizures in patients with the disease when added to a current therapy.
The FDA does not have to act on the recommendations of its experts, but typically does.
A potential approval of the drug, Epidiolex, a final decision on which is due by June 27, would confirm the therapeutic benefits of cannabidiol (CBD) - an active ingredient found in marijuana from which the drug is derived.
Epidiolex is designed to treat Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), rare childhood-onset forms of epilepsy that are among the most resistant to treatment.
“There is little evidence that CBD has meaningful abuse potential,” an FDA staffer said during the meeting.
https://www.reuters.com/article/us-gw-fda/fda...SKBN1HQ2CG
(0)
(0)
$MJ